IS IT POSSIBLE TO REACH « OPTIMAL THERAPY » IN A SPECIALIZED HEART FAILURE CLINIC? Le Boyer A., Gurné O. Cardiologie Cliniques Universitaires St Luc –

Slides:



Advertisements
Similar presentations
Long Distance Titration of Heart Failure Medications by Telephone Calls Anne E. Steckler, RN, Heba Wassif, MD, Kalkidan Bishu, MD, Gardar Sigurdsson, MD,
Advertisements

Cardiac Insufficiency Bisoprolol Study (CIBIS III) Trial
National Service Frameworks Dr Stephen Newell February 2002.
The Importance of Beta-Blockers in Patients with Heart Failure: A Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT) Analysis.
CM-1 ACE Inhibitor Dosing Considerations in CHARM John J.V. McMurray, MD Professor of Medical Cardiology Western Infirmary Glasgow Scotland UK.
Purpose To determine whether metoprolol controlled/extended release
Primary care of hypertensive patients and the risk of acute events Irina Stirbu-Wagner Markus MJ Nielen Maaike Langelaan Robert A. Verheij Joke C. Korevaar.
Institute for General Practice, Johann Wolfgang Goethe-University, Frankfurt, 2004 “HiMoL” A Tool for Case Management for Patients with Congestive Heart.
HEART FAILURE MANAGEMENT -RAAS BLOCKERS FAZIL BISHARA SR- CARDIOLOGY
Management of Chronic Heart Failure SIGN 95
Canadian Diabetes Association Clinical Practice Guidelines Treatment of Diabetes in People with Heart Failure Chapter 28 Jonathan G. Howlett, John C. MacFadyen.
THE ROLE OF THE HEART FAILURE SPECIALIST NURSE NHS Grampian Heart Failure Nurses November 2008.
Inter-professional collaboration in Chronic Care Model and its effect on outcomes of care. Findings from a patient experience survey. Anna Maria Murante.
May 23rd, 2012 Hot topics from the Heart Failure Congress in Belgrade.
Heart Failure Core Measures GMEC QI Presentation.
JONATHAN MANT, MD; ABDALLAH AL-MOHAMMAD, MD; SHARON SWAIN, BA, PHD; AND PHILIPPE LARAMEE,DC,MSC, FOR THE GUIDELINE DEVELOPMENT GROUP CHRIS FONTIMAYOR MS-III.
Priory Fields Patient Participation Group Survey December 2011.
Clinical Effectiveness of Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries With Heart Failure Adrian F. Hernandez, MD, MHS; Gregg.
Heart Failure Ben Starnes MD FACC Interventional Cardiology
ATLAS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for Thrombosis and.
Assessment, Targets, Thresholds and Treatment Bryan Williams NICE clinical guideline 127.
Congestive Heart Failure Quality Initiatives. SRHS History of CHF Focus Team early 90’s, developed Care Map, adopted education materials and guidelines.
L References Application to Clinical Practice The American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) have cooperatively.
European guidelines on the management of stable coronary artery disease Key points & new position for Ivabradine and Trimetazidine ESC 2013 Montalescot.
Patient education tools are key to the follow- up of chronic heart failure patients.
Therapeutic Education: Cancer Patients on chemotherapy: Shamim Akhter QURESHI MBBS,MPH, Ingénieur d’étude(EHESP) 2 nd June 2012 June 2010.
Heart Failure Programs Europe and Belgium Sandra Martin Clinical Nurse Specialist UZ Leuven, Belgium.
Specialized Atrial Fibrillation Clinic reduces cardiovascular morbidity and mortality in patients with atrial fibrillation Jeroen ML Hendriks, MSc Robert.
Quality of care, part 2: heart failure Kim A Eagle MD Albion Walter Hewlett Professor of Internal Medicine Chief, Clinical Cardiology Co-Director, Heart.
1 EFFECT STUDY 2 EFFECT STUDY  Set national cardiac care benchmarks for hospitals to work towards 
To know more visit HeartFailure.com © 2015 Novartis Pharma AG, May 2015, GLCM/HTF/0028 HEART FAILURE DISEASE MANAGEMENT STANDARDS.
10 Points to Remember on An Effective Approach to High Blood Pressure ControlAn Effective Approach to High Blood Pressure Control Summary Prepared by Debabrata.
Compliance with clinical practice guidelines for the treatment and optimization of therapy in heart failure patients in outpatient medicine clinics MaryAnn.
HEART FAILURE TEAM MEMBERSHIP
Heart Failure Supportive Care in 2015 GIL KIMEL MD, MSC, FRCPC Dept. of Medicine St. Paul’s Hospital.
COPD Patient and carers Therapies inc pulm rehab Intermediate care team Social Worker Respiratory Physician EAW/General Physician Case manager/ Community.
Surgical Care FMHGettysburgShady Grove Mont.Gen.CHCWCHS 86% of 383 pts. 90% of 337 pts 86% of 254 pts 93% of 323 pts 78% of 301 pts 93% of 874 pts Percent.
Acute Myocardial Infarction (Heart Attack) Committee Membership: B. Majcher, APRN, C. Mulhall, APRN, K. McLean, MD, M. Jarotkiewicz RRT, MS, Administrative.
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
Impact of a Group Heart Failure Clinic on Patient Outcomes in a Veteran Population Melissa Angell, Pharm.D., CGP Adrienne Matson, Pharm.D., BCPS Kate Schmoll,
COMET: Carvedilol Or Metoprolol European Trial Purpose To compare the effects of carvedilol (a β 1 -, β 2 - and α 1 -receptor blocker) and short-acting.
ELITE - II Study Design  60 yrs; NYHA II - IV; EF  40 % ACEI naive or  7 days in 3 months prior to entry Standard Rx ( ± Dig / Diuretics ), ß - blocker.
Heart Failure- Evidence for use of ace inhibitors & betablockers ACE Inhibiitors CONSENSUS(NEJM 87) & SOLVED (NEJM 91) included in Metaanalysis 7000pts.
CHF Team Approach Peter Carson, MD Jacqueline Gannuscio, MSN, ACNP RN Washington DC.
OVERTURE FDA Cardiovascular and Renal Drugs Advisory Committee Meeting July 19, 2002 Milton Packer, M.D., FACC Columbia University College of Physicians.
Candesartan in Heart Failure Presented at European Society of Cardiology 2003 CHARM Trial.
HEART FAILURE Team Membership Clinical Departments: Cardiology, Cardiovascular Surgery, Nursing, QRM, CCE, Medical Records Project Coordinators: Carmen.
CR-1 Candesartan in HF Benefit/Risk James B. Young, MD Cleveland Clinic Foundation.
HEART FAILURE. Excellent Care 1. Diagnosis 2. ACE-I and B blocker 3. Aldosterone antagonist 4. Exercise 5. Statin and aspirin if CVD 6. Digoxin with AF.
Women reaching equality in health, despite the differences Nowadays women remain the largest CAD population subgroup being under-diagnosed and under-treated.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Heart Failure Services at STH: How it works and how End of Life issues are addressed Dr Soon H Song Consultant Diabetologist Acute Medicine Lead for STH.
HF diagnosis: audit of NTproBNP uptake and outcomes across Sheffield An update on diagnosis and management of HF Dr Abdallah Al-Mohammad, MD, FRCP(Edin),
HEART FAILURE TEAM MEMBERSHIP DEPARTMENTS OF CARDIOLOGY, CARDIOVASCULAR SURGERY, MEDICINE, NURSING, QUALITY AND RESOURCE MANAGEMENT, THE CENTER FOR CLINICAL.
Heart Failure GP teaching session 5 Dec 2016
These slides highlight a presentation at the Late Breaking Trial Session of the American College of Cardiology 52nd Annual Scientific Sessions in Chicago,
PRADO, the return to home programme
JOURNAL REVIEW HEART FAILURE MANAGEMENT – BETA BLOCKERS
Ivabradine – A new option for Heart Failure Patients
CLINICAL DILEMMAS IN HEART FAILURE:
EMPHASIS-HF Extended Follow-up
Carmarthenshire LHB and Hywel Dda Trust
HEART FAILURE TEAM MEMBERSHIP
Section III: Neurohormonal strategies in heart failure
Heart Failure Management Coordinated Care Approaches
CIBIS II: Cardiac Insufficiency Bisoprolol Study II
Fig. 2. Evidence-based medication prescriptions
Uptitration of Medications in HF: Start Low but Aim High and Stay High
Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)
Presentation transcript:

IS IT POSSIBLE TO REACH « OPTIMAL THERAPY » IN A SPECIALIZED HEART FAILURE CLINIC? Le Boyer A., Gurné O. Cardiologie Cliniques Universitaires St Luc – UCL Bruxelles PRACTICAL REALISATION AND ADVANTAGE OF HAVING A HEART FAILURE CLINIC IN BELGIUM

HEART FAILURE CLINIC GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC HEART FAILURE - ESC 2005 An organized system of specialist heart failure care - improves symptoms and reduces hospitalizations Class of recommandation I, Level of evidence A - improves mortality Class of recommandation IIA, Level of evidence B

GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC HEART FAILURE - ESC 2005 Various models have been tested (heart failure clinics, nurse-led home visits,and/or telephone follow-up, multidisciplinary care, extended home care services and telemonitoring,…) It is not clear which model is superior It is likely that the optimal model will depend on local circumstances and resources and whether the model is designed for specific sub-groups of patients

?

THE PROBLEM (S) PAST WAS NOT ALWAYS EASY (PRESENT ?) –Relations between « cardiologists » within the same institution –Relations outside the hospital Cardiologists working in an hospital or outside Cardiologist in the University or in Periphery General practionners and (our) hospital and specialists PROBLEM OF BUDGET –Could be paradoxal « a priori » … but in Belgium… –« un investissement de départ » THESE PROBLEMS ARE EXITING EVERYWHERE

THE PROBLEM (S) MIND TO BE CHANGED –DOCTOR = THE ONE who knows (everything) and who does (everything) –patient = the one who is taking the pills without asking any questions –Learn to work in a team –Individualism of the doctors –The patient can – should be an actor of his own health THESE PROBLEMS ARE EXITING EVEYWHERE

Heart Failure Clinic - St Luc Hospital Hospital based Nurse led Mainly taking in charge hospitalized patients in cardiology (EF < 35%) –Education –Coordination MD (cardiologist, GP Psychologist Physiotherapist Dietician Nurses of the cardiology unit Home care (AUXAD : logistical support at home) Palliative care –Registry –Follow-up of patients (phone calls ><)

Number of CHF patients inclusion extrapolé

Number of CHF patients phone calls extrapolé

INCLUSION N = 543 patients –Taken from a registry of 1033 patients Ejection fraction < 35%(5 oct 2007) Patients inclusion was made for this survey according to –Follow-up available at 6 months (or death before) in all patients –No Cardiac surgery or PCI during the 6 first months of follow-up Inclusion data obtained at the end of an hospitalization (for the treatment) Comparison between follow-up By a specialized structure n = 163 By another structure (± control group)n = 380

FOLLOW-UP specializedheart failure unit Control Group Incl/ 6m m % %

ACE TREATMENT % Specialized CHF clinicControl Group P=0.10 P=0.06

INH A II TREATMENT % Specialized CHF clinicControl group

ACE or AII INHIBITORS TREATMENT % Specialized CHF clinicControl group P=0.02

BB TREATMENT % Specialized CHF clinicControl group P=0.001

ACE /AII INHIBITORS and BB TREATMENT % Specialized CHF clinicControl group P=0.001

SPIRONOLACTONE TREATMENT % Specialized CHF clinicControl group P=0.004 P=0.01

ACE /AII INHIBITORS and BB and Spironolactone TREATMENT % Specialized CHF clinicControl group P=0.001

Relative ACE INH mean daily dose (in % « max dose » Specialized CHF follow-up Control group

Beta Blockers mean daily dose bisoprololcarvedilol bisoprolol carvedilol Specialized CHF clinic Control group

Relative BB mean daily dose (in % « max dose » Specialized CHF follow-upControl group

% Specialized CHF clinicControl group Combined death or CHF hospitalization events P=0.001 P=0.01

CONCLUSION In a relatively unselected population, it is posible to reach a high percentage of patients treated by an ACE Inh or an Inh A II AND a Beta Blocker Higher use of Spironolactone was also achieved The dosage of these compounds can also be simultaneously more increased, even if the target doses described in the large randomised studies performed were not achieved

CONCLUSION This approach translate in a better prognosis for these patients It could explained - partially - the results obtained in « Heart Failure Clinics » Others factors, such as education and possibility to maintain a closer contact (telephone, consultation) with the patients, play certainly also an important role

ALDACTONE EPLERENONE ACEI ARB